Related Experiment Video
Updated: Aug 8, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
[Changes in insulin secretion in familial combined hyperlipemia]
J F Ascaso1, J Sales, A Priego
1Servicio de Endocrinología, Hospital Clínico Universitario, Universidad de Valencia.
Medicina Clinica
|April 12, 1997
Summary
Familial combined hyperlipidemia (FCH) is linked to higher insulin levels and impaired glucose metabolism, even without diabetes. This hyperinsulinism may explain the increased cardiovascular disease risk in FCH patients.
Area of Science:
- Endocrinology
- Metabolic Syndrome
- Cardiovascular Risk Factors
Background:
- Familial combined hyperlipidemia (FCH) is associated with a higher incidence of coronary heart disease.
- The underlying metabolic abnormalities contributing to this risk are not fully understood.
Purpose of the Study:
- To investigate glucose and insulin metabolism abnormalities in non-diabetic individuals with FCH.
- To determine the role of metabolic factors in the elevated cardiovascular disease risk in FCH.
Main Methods:
- A study involving 42 non-diabetic FCH subjects and 42 age/sex-matched controls.
- Assessment of plasma lipids, lipoproteins, glucose, and insulin levels, including during an oral glucose tolerance test (OGTT).
Main Results:
- FCH subjects exhibited higher blood pressure, lipids, and apo B levels compared to controls.
- Significantly elevated plasma glucose and insulin levels were observed in FCH subjects during OGTT.
- A high prevalence of hyperinsulinemia (basal and post-OGTT) was found in the FCH group.
Conclusions:
- Hyperinsulinism is common in non-diabetic FCH patients, irrespective of glucose tolerance.
- This hyperinsulinism is a potential contributor to the heightened cardiovascular risk observed in FCH.
Related Concept Videos
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.